We have recently introduced liquid chromatographytandem mass spectrometry (LC-MS/MS) for 25-hydroxyvitamin D 2 (25OHD 2 ) and 25OHD 3 testing. During subsequent clinical use, we identified significantly elevated results in some infants. We hypothesized this might represent assay interference caused by C-3 epimers of 25OHD 2 or 25OHD 3 .
V ITAMIN D LABORATORY testing has increased sig-
nificantly during the last decade because of an increasing awareness that vitamin D deficiency is very common and can increase fracture and, possibly, cancer risk (1) (2) (3) (4) (5) (6) . Measurement of total 25-hydroxyvitamin D (25-OHD; sum of 25OHD 2 and 25OHD 3 ) is the preferred test for assessing vitamin D status, because it has a long serum half-life and its concentration is considered to be in equilibrium with vitamin D body stores (7) (8) (9) (10) .
Unfortunately, there are substantial discrepancies between test results obtained with different 25-OHD assays. Most 25-OHD assays are competitive immunoassays or competitive assays based on vitamin D binding proteins (11, 12) . For such assays, 25-OHD is a difficult analyte because of its hydrophobicity and relatively low serum concentrations (10, 12) . This often necessitates sample extraction and concentration before analysis, potentially increasing assay variability. Furthermore, equal detection of 25OHD 2 and 25OHD 3 represents a challenge, in particular for assays based on vitamin D binding protein, because binding proteins from many species show higher affinity for 25OHD 3 than for 25OHD 2 (13) . As a consequence of all these factors, only 50 -60% of the approximately 100 laboratories that participate in the international quality assessment scheme for vitamin D metabolites (DEQAS), meet performance criteria consistently, and the results obtained for the same sample can differ up to 2-to 4-fold, sometimes even for the same assay, when performed in different laboratories (11) .
In an attempt to overcome these problems, we replaced our previous 25-OHD extracted RIA with a candidate reference method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) (14, 15) . The method uses deuterated 25OHD 3 as an internal standard in each sample, thereby enabling correction of extraction variability and allowing accurate, separate measurement of 25OHD 2 and 25OHD 3 . In our assay validation, it agreed well with our previous RIA, which some authors have considered a gold standard ( Fig. 1) (12, 16) .
In subsequent practice, we became aware of a small number of unexpectedly high 25-OHD results in infants. We became concerned that these might result from assay interference. Although most natural vitamin D metabolites and vitamin-D-related drugs are either too different in chemical structure to be a potential interferent or were excluded as such during our assay validation, some isomers of 25-OHD could potentially interfere. Epimers in particular have identical chemical structures except for a single site of molecular asymmetry and might therefore display very similar chromatography and give rise to the same MS/MS ion pairs. The C-3 epimers of 25OHD 2 and 25OHD 3 , 3-epi-25OHD 2 and 3-epi-25OHD 3 , caught our attention specifically, because C-3 epimerization of 25OHD 3 (22, 23) but has significantly reduced calcemic effects (24, 25) . Distinguishing between 25-OHD and 3-epi-25-OHD could therefore be of relevance. The C-3 epimers can be converted to their respective 3-epi-1,25-OHD metabolites, and their presence might also be an indicator of elevated C-3 epimerization at the level of 1,25-OHD synthesis.
However, it is currently unknown whether C-3 epimers of 25-OHD can be found in humans in significant circulating concentrations. We hypothesized that this might be the case in some young children. Immaturity of, possibly hepatic, vitamin D metabolism in some infants could favor formation of C-3 epimers. In particular, enzymes from the cytochrome P450 family, notably CYP24, CYP27A1, and CYP27B1, are known to be involved in various facets of vitamin D metabolism and are expressed at particularly high levels in the liver. We therefore modified our existing LC-MS/MS method to also allow detection of 3-epi-25OHD 2 and 3-epi-25OHD 3 and studied a series of pediatric samples, normal adult samples, and adult samples from patients with impaired hepatic function.
Patients and Methods
The studies were approved by the Mayo Clinic institutional review board.
Our study aims were to 1) determine the prevalence of detectable 3-epi-25OHD 2 or 3-epi-25OHD 3 in human serum, and 2) determine the patient populations that might be affected.
The samples for this study were consecutive waste specimens from routine testing received in our laboratory, selected based only on age and, for adult samples, the likely presence or absence of hepatic dysfunction. They included samples from four groups of subjects: group 1, children less than 1 yr old (n ϭ 183; 116 males and 67 females); group 2, children 1-18 yr old (n ϭ 47; 19 males and 28 females); group 3, adults aged 20 -87 yr with liver disease (hepatoma surveillance patients with elevated serum ␣-fetoprotein concentrations; n ϭ 53; 25 males and 28 Standards/calibrators, internal standard, and controls 25OHD 2 and 25OHD 3 standards/calibrators and 25OHD 3 -d 6 internal standard were purchased from Sigma Chemical Co. (St. Louis, MO) and As Vitas (Oslo, Norway), respectively. Manufacturer-stated concentrations were confirmed by UV spectrophotometry. The 3-epi-25OHD 3 standards were prepared and verified by one of the authors (G.S.R.) as described previously (21) . Stock solutions of all standards were stored at Ϫ20 C.
Three pools of control samples each were prepared for 25OHD 2 and 25OHD 3 . Control target values of 25OHD 2 were established at 4.2, 17, 42, and 110 ng/ml (10.2, 41.3, 101.9, and 267 nmol/liter). Target values of 25OHD 3 were established at 1.7, 24, 55, and 132 ng/ml (4.25, 60, 137.5, and 330 nmol/liter).
Sample preparation
Twenty-five microliters of working internal standard at a concentration of 200 ng/ml (492.6 nmol/liter) were added to each 200 l of patient samples, controls, or calibrators. The mixtures were incubated for 15 min at room temperature to allow the internal standard to equilibrate with binding proteins. Proteins were precipitated by addition of 200 l of acetonitrile and centrifugation. The supernatant was transferred to 96-well plates for analysis.
LC-MS/MS
For the standard 25-OHD method, online extraction and HPLC chromatography of the supernatants were performed using a TX4 Turbo Flow system (Cohesive Technologies, Franklin, MA) with 1.0 ϫ 50 mm Cyclone extraction columns and 3.3 cm ϫ 4.6 mm, 3-m LC-18 (Supelco, St. Louis, MO) analytical columns. After online extraction, the analytes were eluted onto the analytical column for 90 sec with a mobile phase of 39.5% vol/vol methanol, 0.005% vol/vol formic acid. There was a step gradient to 87% vol/vol methanol, 0.005% vol/vol formic acid for the analytical column. The analytes then entered an API 4000 triplequadrupole mass spectrometer (ABI-Sciex, Toronto, Canada) and were ionized in an atmospheric-pressure chemical-ionization source and detected by multiple reaction monitoring of the following ion pairs: m/z 413.0/395.3 for 25OHD 2 , m/z 401.4/383.3 for 25OHD 3 , and m/z 407.4/ 389.5 for 25OHD 3 -d 6 . The raw signals of 25OHD 2 and 25OHD 3 in the calibrators, controls, and samples were normalized to their respective internal standard 25OHD 3 -d 6 signals, and concentrations in the samples and controls were calculated off the normalized six-point calibration curves [0 -200 ng/ml (0 -500 nmol/liter)]. Samples with concentrations that exceeded the highest calibrator were diluted and run again. The total 25-OHD concentrations of each control and sample were calculated by summing the measured values of 25OHD 2 and 25OHD 3 .
For separation of epimers, the standard LC-18 column was replaced with a longer 5-dinitrobenzoyl-(R)-phenylglycine column (Chirex-PGLY and DNB 250 ϫ 4.6 mm; Phenomenex, Torrance, CA) and 100 l of the supernatant was injected. The step gradient extends only up to 67% vol/vol methanol, 0.005% vol/vol formic acid at an analytical column flow rate of 0.9 ml/min. The mass spectrometer settings remained unchanged. The concentrations of 25OHD 2 , 25OHD 3 , and 25-OHD were calculated as above. The concentrations of any detected C-3 epimers of 25OHD 2 or 25OHD 3 were also calculated off the normalized 25OHD 2 and 25OHD 3 calibration curves, and the total 3-epi-25-OHD concentration is the sum of 3-epi-25OHD 2 and 3-epi-25OHD 3 concentrations.
Assay performance parameters
The performance of the two LC-MS/MS methods was similar for 25OHD 2 and 25OHD 3 . Interassay coefficients of variation (CV) for the 25OHD 2 controls were 14, 5, 7, and 6%, respectively. Corresponding interassay CV for 25OHD 3 controls were 13, 8, 8 , and 6%. The recovery of analyte spiked into patient samples was 82-115% (mean, 102%) of predicted for 25OHD 2 and 88 -115% (mean, 103%) for 25OHD 3 . The 25-OHD concentrations obtained by the two LC-MS/MS methods matched each other closely (Fig. 3) .
Extracted RIA
In the 25-OHD RIA (Diasorin, Stillwater, MN), samples were extracted with acetonitrile, followed by a competitive RIA. According to the Diasorin packet insert, the RIA uses 125 I-labeled 25OHD 3 and a goat polyclonal antibody specific to the 25-OH-containing side chain; in the original published assay description, a rabbit-derived antibody was used (26, 27) . A secondary antibody against the primary antibody was used as a precipitating reagent.
Interassay CV for this assay range from 8.5-14.4% across the reportable range. The assay compares closely with the LC-MS/MS standard method (Fig. 1) .
Testing of study samples
All study samples were assayed by the standard and the modified LC-MS/MS method. In addition, all samples with total 25-OHD concentrations more than 100 ng/ml (250 nmol/liter) underwent confirmatory retesting. Chromatograms obtained with the modified method were inspected for the presence of C-3 epimer peaks. All detectable 25OHD 2 , 25OHD 3 , 3-epi-25OHD 2 , and 3-epi-25OHD 3 peaks were quantitated, as described above, and the total 25-OHD and 3-epi-25-OHD concentrations were calculated. For every sample with detectable C-3 epimer peaks, we calculated the percent contribution of total 3-epi-25-OHD to the corresponding total 25-OHD concentration.
We also assayed all samples with epimer peaks and sufficient residual sample volume with the Diasorin RIA. The results were compared with the total 25-OHD values obtained by the modified LC-MS/MS assay.
Data analysis
The frequencies of occurrences of C-3 epimers were tabulated for the different study groups and compared with each other by 2 -analysis, Passing-Bablock linear fit with 95% CI is superimposed. B, The same dataset after removal of data points more than 100 ng/ml. using appropriate degrees of freedom. In each group, 2 testing was also used to compare the likelihood for the presence of C-3 epimer peaks depending on whether patients had detectable 25OHD 2 or 25OHD 3 as well as to determine whether there was a relationship between patient gender and the presence of detectable C-3 epimers in any of the groups. Yates correction was used for all single degree of freedom 2 tests. Regression analysis and ANOVA, respectively, were applied to all cases with detectable C-3 epimers to determine whether there was any relationship between the percent contribution of the C-3 epimers to the total 25-OHD values and the patient's age or gender. Statistical comparisons between different analytical methods were performed using Passing-Bablock linear regression.
For all statistical tests, a P value of Ͻ0.05 was considered significant, corrected if necessary for degrees of freedom or multiple comparisons.
Results
In group 1 (children Ͻ1 yr old), the total 25-OHD concentrations (including the contribution of C-3 epimers) ranged from 0 -188 ng/ml [0 -470 nmol/liter; median, 29.3 ng/ml (73.2 nmol/liter), mean, 34.2 ng/ml (85.5 nmol/liter)], with 172 of the 183 children having detectable levels of 25OHD 2 or 25OHD 3 . We detected 25OHD 3 in 163 of these 172. Thirty children also had detectable levels of 25OHD 2 . An additional nine children had detectable 25OHD 2 but no detectable 25OHD 3 . We did not detect any 25OHD 3 or 25OHD 2 in 11 subjects.
We found 3-epi-25OHD 2 (n ϭ 2) or 3-epi-25OHD 3 (n ϭ 38) in 39 of the 172 children (22.7%) with detectable 25OHD 2 or 25OHD 3 (Fig. 4 ). All subjects with detectable C-3 epimers also had detectable 25OHD 2 or 25OHD 3 . Among the 39 epimer-positive children, 31 had only detectable 25OHD 3 , one had only detectable 25OHD 2 , and seven had detectable 25OHD 2 and 25OHD 3 . Of the eight children in this subgroup with detectable 25OHD 2 , two, including the one who only had 25OHD 2 , had 3-epi-25OHD 2 peaks. 3-Epi-25OHD 3 There was sufficient sample volume for RIA testing in 34 of the 39 children with detectable 3-epi-25OHD 2 or 3-epi-25OHD 3 . The standard LC-MS/MS method and the Diasorin RIA were in good agreement in this group with a PassingBablock regression slope of 1.059, an intercept of Ϫ5.8, and a correlation coefficient of 0.8.
There was a greater likelihood of detectable 3-epi-25OHD 3 than 3-epi-25OHD 2 , with 38 of 163 25OHD 3 -positive individuals having 3-epi-25OHD 3 peaks, whereas only two of 39 patients with detectable 25OHD 2 showed 3-epi-25OHD 2 peaks [odds ratio ϭ 5.62; confidence interval (CI) ϭ 1.24 -35.40; 2 ϭ 5.46; P Ͻ 0.02]. In the patients with detectable C-3 epimer peaks, regression analysis revealed an inverse relationship between patient age and percentage of total 3-epi-25-OHD detected, with a linear fit resulting in a correlation coefficient 0.48 (P Ͻ 0.002), whereas an exponential decay function fit resulted in a marginally higher correlation coefficient of 0.49 (P Ͻ 0.007) (Fig. 5) .
Gender was not related to the presence or absence of C-3 epimer peaks, nor did it correlate with total 3-epi-25-OHD concentrations or percentages.
In group 2 (children 1-18 yr of age), total 25-OHD concentrations were 0 -58 ng/ml [0 -145 nmol/liter; median, 34 ng/ml (85 nmol/liter); mean, 33 ng/ml (82.5 nmol/liter)]. Thirty-nine children had only detectable 25OHD 3 , six had detectable 25OHD 2 and 25OHD 3 , one had only 25OHD 2 , and one had neither 25OHD 2 nor 25OHD 3 . We did not detect any C-3 epimer peaks in any of these 47 older children.
Total 25-OHD concentrations in group 3 (adults with compromised liver function, 20 -87 yr old) were 0 -57 ng/ml [0 -142.5 nmol/liter; median, 17 ng/ml (42.5 nmol/liter); mean, 19 ng/ml (47.5 nmol/liter)]. Three patients had no detectable circulating 25-OHD, 39 had detectable 25OHD 3 , 10 had detectable 25OHD 2 and 25OHD 3 , and one had only 25OHD 2 . No patient had any detectable C-3 epimer peaks.
In group 4, the 147 adults aged 19 -91 yr, without known liver disease, total 25-OHD levels were 4 -330 ng/ml [10 -825 nmol/liter; median, 28.5 ng/ml (71.2 nmol/liter); mean, 31.3 ng/ml (78.2 nmol/liter)]. All patients had detectable 25OHD 3 , and 47 also had detectable 25OHD 2 . No C-3 epimer peaks were detected.
The differences in C-3 epimer detection rates between the four groups were highly significant with an overall 2 (three degrees of freedom) of 60.81 (P Ͻ 0.00001), whereas individual paired comparisons of group 1 against groups 2, 3, and 4 yielded 2 values of 11.21 (P Ͻ 0.00082; multicomparison corrected P Ͻ 0.00246), 12.23 (P Ͻ 0.00047; multicomparison corrected P Ͻ 0.00141), and 35.89 (P Ͻ 0.00001; multicomparison corrected P Ͻ 0.00003), respectively. There were no significant differences between groups 2, 3, and 4.
Discussion
Our study shows that C-3 epimers of 25OHD 2 or 25OHD 3 can be found in significant concentrations in a sizable minority of very young children who undergo clinical 25-OHD testing. Although we detected both 3-epi-25OHD 3 , presumably endogenous, as well as 3-epi-25OHD 2 , most likely from supplements, our data suggest that 25OHD 3 may be more likely to undergo C-3 epimerization than 25OHD 2 .
Within the limitations of our study, the phenomenon seems to be confined to children under the age of 1 yr. Furthermore, within this group, it is inversely correlated with age (Fig. 5 ). This suggests that high rates of C-3 epimerization might be a function of immaturity of vitamin D metabolism. It also suggests that C-3 epimerization could be a major metabolic pathway for 25-OHD under certain circumstances. In fact, recent in vitro studies have hinted at the possibility that C-3 epimerization of 25-OHD could play an equal or more important role than epimerization of 1,25-OHD. Microsomal enzyme systems from a variety of cell lines show greater specificity and substrate conversion rates for the C-3 epimerization of 25-OHD than for the corresponding conversion of 1,25-OHD (28) . However, the exact nature of the conditions, which might favor C-3 epimerization of 25-OHD, remains to be determined. Our studies seem to exclude deranged hepatic metabolism, despite the fact that hepatic microsomal cytochrome enzymes are known to play a major role in vitamin D metabolism and the associated clinical observation that liver patients often have biochemical evidence of disturbed vitamin D metabolism. This is consistent with in vitro experiments that have failed to identify the enzyme involved in C-3 epimerization of vitamin D metabolites among a group of known enzymes in the vitamin D pathway, including CYP24, CYP27A1, CYP27B1, and 3(␣-␤)-hydroxysteroid epimerase (28) . It therefore appears that although microsomal enzyme systems seem to play a role in C-3 epimerization of vitamin D metabolites, the actual enzymes involved are distinct from the classical hepatic enzyme systems of vitamin D metabolism.
The immediate clinical consequence of our findings lies in the potential for inaccurate measurement of 25-OHD in young children. In our laboratory, we have changed our practice based on this study. We now use the alternative LC-MS/MS method for all 25-OHD measurements in children under the age of 1 yr. It is interesting to speculate how other LC-MS/MS or HPLC-UV detection methods in other laboratories might be performing with regard to C-3 epimer separation. Similarly, for the most part, it remains to be determined whether the various assays based on vitamin D binding protein and immunoassays are able to distinguish 25-OHD from its C-3 epimers. Cross-reactivity of 25-OHD assays with one or several of the over 40 known natural vitamin D metabolites is common (10, 29 (26, 27) . Traditionally, these and similar cross-reactivities in other 25-OHD assays have been regarded as clinically irrelevant because the serum concentrations of the cross-reactants are between one and two orders of magnitude lower than those of 25-OHD. However, as we have shown, 3-epi-25OHD 2 and 3-epi-25OHD 3 concentrations are much higher and could represent a relevant interference. Reassuringly, the Diasorin extracted RIA does not appear to cross-react with 3-epi-25OHD 2 or 3-epi-25OHD 3 , giving accurate total 25-OHD results that correlate well with our modified LC-MS/MS method. However, we did not study any of the other 25-OHD assays that are currently in clinical use in the United States or Europe, and some of these might display cross-reactivity with 3-epi-25OHD 2 or 3-epi-25OHD 3 .
Another issue that needs to be discussed is whether distinguishing between 25-OHD and its C-3 epimers is of clinical importance. Although the phenomenon is fairly prevalent among young infants and significant concentrations of 3-epi-25-OHD are found in affected children, the biological consequences depend on whether 25-OHD and its C-3 epimers differ in their physiological effects. This question can be separated into two parts. Because 25-OHD is a prohormone that needs to be converted into 1,25-OHD, we need to determine first whether 3-epi-25-OHD is converted to 3-epi-1,25-OHD and then to dissect the differential biological effects of 1,25-OHD vs. 3-epi-1,25-OHD.
With regard to 3-epi-25-OHD conversion to downstream metabolites, the literature indicates that it is a substrate for 1␣-hydroxylase and is converted into 3-epi-1,25-OHD (21) . In addition, the conditions that favor C-3 epimerization of 25-OHD probably also favor the same metabolic pathway for 1,25-OHD, possibly involving extrarenal tissues (18 -21, 30, 31) (Fig. 2) . It therefore seems highly probable that children with detectable 3-epi-25-OHD might also have 3-epi-1,25-OHD. Final proof, however, will have to await the development of a method for measurement of serum 3-epi-1,25-OHD.
The issue of the bioactivity of 1,25-OHD vs. that of 3-epi-1,25-OHD is more complex. 3-Epi-1,25-OHD can stimulate gene transcription through the vitamin D receptor (VDR) despite the fact that it appears to have weaker binding affinity to the VDR than 1,25-OHD (32, 33) . The lower receptor binding affinity does not translate into universally reduced biological effects of 3-epi-1,25-OHD in all vitamin-D-respon-sive tissues. The transcriptional, as well as the ultimate physiological, response to 3-epi-1,25-OHD has been found to be highly variable for different VDR-regulated genes in different tissues (20, 22, 23, 25, 30, 31, 34, 35) . These differences may in part relate to the longer half-life of 3-epi-1,25-OHD (30) but could also reflect selective partial agonistic-antagonist effects, such as have been described for a number of synthetic vitamin D analogs (36) . Potential examples of apparently contradictory biological effects include the C-3 epimers' reduced calcemic properties and less potent gene-regulatory effects on some VDR-responsive genes involved in bone metabolism, such as osteocalcin (18, 24, 25, 34) , whereas, on the other hand, suppression of gene transcription of PTH, antiproliferative effects in epithelial cells, and induction of surfactant gene transcription in pulmonary type II alveolar cells are comparable to 1,25-OHD (22, 23, 30, 35) .
In conclusion, significant serum concentrations of 3-epi-25-OHD are commonly found in infants. Although the biological consequences of this phenomenon remain uncertain, in clinical practice, it can lead to overestimation of serum 25-OHD levels. Because the calcemic effects of the active downstream metabolite 3-epi-1,25-OHD are low, this might result in inappropriate reduction or omission of 25-OHD treatment in some children or unjustified anxiety about possible 25-OHD overdosing or toxicity in other children. Serum 25-OHD in children below the age of one should therefore be measured with an assay that either does not cross-react with 3-epi-25-OHD or allows unequivocal separation of 3-epi-25-OHD from 25-OHD. Currently, the only assays that we have verified to fulfill these requirements are our modified LC-MS/MS assay and the extracted Diasorin RIA. Laboratories that use other assays should evaluate whether their assays measure 25-OHD accurately in the presence of 3-epi-25-OHD.
